Neuphoria Therapeutics Inc. Foreign Currency Transaction Gain Loss Unrealized After Tax
Neuphoria Therapeutics Inc. (NEUP) reported Foreign Currency Transaction Gain Loss Unrealized After Tax of $781.90 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax · last filed 2026-09-18
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for the quarter ending 2026-06-30 was $4.20K, a 99.61% decline year-over-year.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for the quarter ending 2026-03-31 was $157.90K.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for the quarter ending 2025-12-31 was $570.58K.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for the quarter ending 2025-09-30 was $49.22K, a 91.59% decline year-over-year.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for fiscal 2026 was $781.90K, a 363.95% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for fiscal 2025 was $168.53K, a 272.95% increase from fiscal 2024.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for fiscal 2024 was $45.19K.
- Neuphoria Therapeutics Inc. foreign currency transaction gain loss unrealized after tax for fiscal 2023 was -$1.04M.
| Period end | Foreign Currency Transaction Gain Loss Unrealized After Tax 3 month | Foreign Currency Transaction Gain Loss Unrealized After Tax 6 month | Foreign Currency Transaction Gain Loss Unrealized After Tax 9 month | Foreign Currency Transaction Gain Loss Unrealized After Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $162.09K derived: sum of 2 quarters · filed 2026-09-18 | $732.67K derived: sum of 3 quarters · filed 2026-09-18 | $781.90K 10-K · filed 2026-09-18 |
| 2026-03-31 | $157.90K 10-Q · filed 2026-05-15 | $728.48K derived: sum of 2 quarters · filed 2026-05-15 | $777.70K 10-Q · filed 2026-05-15 | $1.85M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $570.58K 10-Q · filed 2026-02-17 | $619.80K 10-Q · filed 2026-02-17 | $1.69M derived: sum of 3 quarters · filed 2026-09-18 | $1.49M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $49.22K 10-Q · filed 2025-11-14 | $1.12M derived: sum of 2 quarters · filed 2026-09-18 | $920.80K derived: sum of 3 quarters · filed 2026-09-18 | -$367.63K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $871.58K derived: sum of 2 quarters · filed 2026-09-18 | -$416.85K derived: sum of 3 quarters · filed 2026-09-18 | $168.53K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$195.82K 10-Q · filed 2026-05-15 | -$1.48M derived: sum of 2 quarters · filed 2026-05-15 | -$898.87K 10-Q · filed 2026-05-15 | -$679.35K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$1.29M 10-Q · filed 2026-02-17 | -$703.05K 10-Q · filed 2026-02-17 | -$483.53K derived: sum of 3 quarters · filed 2026-02-17 | -$1.05M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $585.38K 10-Q · filed 2025-11-14 | $804.90K derived: sum of 2 quarters · filed 2025-11-14 | $242.95K derived: sum of 3 quarters · filed 2025-11-14 | $694.04K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $219.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$342.43K derived: sum of 2 quarters · filed 2025-09-29 | $108.66K derived: sum of 3 quarters · filed 2025-09-29 | $45.19K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$561.95K 10-Q · filed 2025-05-20 | -$110.86K derived: sum of 2 quarters · filed 2025-05-20 | -$174.33K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $451.08K 10-Q · filed 2025-02-14 | $387.62K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$63.47K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$1.04M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |